WC
DGX icon

Whitney & Co’s Quest Diagnostics DGX Stock Holding History

Whitney & Co’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-25,228
Closed -$3.45M – 125
2022
Q1 		$3.45M Sell
25,228
-291
-1% -$40.6K 0.53% 50
2021
Q4 		$4.42M Sell
25,519
-187
-0.7% -$28.5K 0.65% 50
2021
Q3 		$3.73M Sell
25,706
-86
-0.3% -$12.6K 0.6% 52
2021
Q2 		$3.4M Sell
25,792
-89
-0.3% -$11.7K 0.54% 53
2021
Q1 		$3.32M Buy
25,881
+314
+1% +$38.7K 0.58% 51
2020
Q4 		$3.22M Sell
25,567
-637
-2% -$77.7K 0.52% 56
2020
Q3 		$3M Buy
+26,204
New +$3.1M 0.56% 50
2018
Q4 		– Sell
-646
Closed -$63K – 189
2018
Q3 		$63K Buy
646
+46
+8% +$5.04K 0.02% 165
2018
Q2 		$66K Hold
600
– – 0.02% 149
2018
Q1 		$60K Buy
+600
New +$61.5K 0.02% 165

Other funds holding DGX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DSA
Davis Selected Advisers Tucson, Arizona $21.8B AUM 23.45% 1-Year Est. Return

Whitney & Co's DGX Position: Q2 2022 in Review

Whitney & Co sold out of Quest Diagnostics (DGX) in Q2 2022, closing a stake of 25,228 shares — an estimated $3.45M sold.

Whitney & Co first reported a position in DGX in Q1 2018 and held it in 10 quarters. The position peaked at $4.42M in Q4 2021. 851 funds tracked by Wall St. Rank hold DGX as of Q2 2022.

  • Whitney & Co reported no remaining Quest Diagnostics position as of Q2 2022 after selling out during the quarter.
  • Whitney & Co sold 25,228 Quest Diagnostics shares in Q2 2022, an estimated $3.45M.
  • Whitney & Co first reported a position in Quest Diagnostics in Q1 2018 and held it in 10 quarters.
  • Whitney & Co's Quest Diagnostics position peaked at $4.42M in Q4 2021.
  • 851 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2022.

Based on Whitney & Co's 13F filing for Q2 2022, filed 5 Aug 2022.